Disc Medicine, Inc. IRON
Updated: 11 Aug 2026
No signal published yet
We already track Disc Medicine and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Disc Medicine, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Disc Medicine free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 30, 2026, Disc Medicine reported its second-quarter 2026 financial results and provided a business update. The company confirmed alignment with the FDA that its Phase 3 APOLLO study of bitopertin can serve as the basis for a CRL response, with topline data expected in Q4 2026. Additionally, Disc ended the quarter with $717.7 million in cash, cash equivalents, and marketable securities.
What Firelda Watch includes for Disc Medicine, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Disc Medicine, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Disc Medicine free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more